Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis
A phase 3 trial of Ravulizumab in childhood cancers, run by Alexion Pharmaceuticals, Inc., active and no longer recruiting.
Overview
Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis is a phase 3 interventional study registered as NCT05644561 by Alexion Pharmaceuticals, Inc., with 12 participants enrolled, started 2023-06-24 and due to reach its primary completion in 2026-07-15. Interventions recorded: Ravulizumab.
Similar pages
not linked directly; found by shared links- TrialPK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Shares Childhood cancers (all types), AstraZeneca and the tag pipeline.
- TrialDurvalumab and Tremelimumab for Pediatric Malignancies
Shares Childhood cancers (all types), AstraZeneca and the tag pipeline.
- TrialOpen-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC
Shares Childhood cancers (all types) and the tag pipeline.
- TrialPhase II Study of QLC2519 in Pediatric Solid Tumor Participants
Shares Childhood cancers (all types) and the tag pipeline.
- TrialStudy to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
Shares Childhood cancers (all types) and the tag pipeline.
- TrialCEB-01 in Paediatrics With Locally Resectable Abdominal Tumours
Shares Childhood cancers (all types) and the tag pipeline.
- TrialInvestigation of Remimazolam in Children Undergoing Sedation for Medical Procedures
Shares Childhood cancers (all types) and the tag pipeline.
- TrialAlpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Shares Childhood cancers (all types) and the tag pipeline.